Some features of beckman.com will be unavailable from 8:00 p.m. PDT Saturday, December 7 until 12:00 a.m. PDT, Sunday, December 8 for planned maintenance. During this time, you will not be able to log in to use account features such as online shopping, shopping lists and order tracking.
Please ensure your orders are processed prior to this maintenance period or contact Client Services for additional assistance.
Yes, just as tumors are able to develop resistance to chemotherapies, tumors can also develop resistance to immunotherapies. How resistance builds is a matter currently under investigation. There is some evidence to suggest that resistance is an adaptation controlled by epigenetic modifications to the cancer cell genome.1 Other researchers have identified the apoptosis of tumor-infiltrating lymphocytes as playing a causative role.2 As new research continues, it’s likely that research will uncover several mechanisms by which tumors work to evade the activity of anticancer immunotherapies. Only once the causes of resistance are fully understood and mitigated will immunotherapy reach its fullest potential.
1. D. Zingg, et al., “The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy,” Cell Rep 20 (4):854, 2017.
2. J. Zhu, et al., “Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes,” Nat. Comm 8:1404, 2017.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.